Evidence map›Paper›PMID 41852554›Full record

ArticleOpen forum infectious diseases2026

Use of DOOR and Win-Ratio Analysis in a Secondary Evaluation of a Histoplasmosis Clinical Trial.

Tarsila Vieceli, Biyue Dai, Diego R Falci, Daiane Dalla-Lana, Cassia S M Godoy, Renata B A Soares, Monica B Bay, Hareton Vechi, Terezinha M J S Leitao, Lisandra S Damasceno and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tarsila VieceliPost-graduation Program in Pathology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0001-6274-1320
Biyue DaiDivision of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-4747-3687
Diego R FalciInfectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0002-8683-3833
Daiane Dalla-LanaPost-graduation Program in Pathology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil.
Cassia S M GodoyInfectious Diseases Service, Hospital de Doenças Tropicais, Goiânia, Brazil.ORCID https://orcid.org/0000-0003-4893-0541
Renata B A SoaresInfectious Diseases Service, Hospital de Doenças Tropicais, Goiânia, Brazil.ORCID https://orcid.org/0000-0003-1029-325X
Monica B BayDepartment of Infectious Diseases, Federal University of Rio Grande do Norte, Natal, Brazil.ORCID https://orcid.org/0000-0002-5569-1756
Hareton VechiDepartment of Infectious Diseases, Federal University of Rio Grande do Norte, Natal, Brazil.ORCID https://orcid.org/0000-0001-7845-3921
Terezinha M J S LeitaoDepartment of Community Health, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Lisandra S DamascenoDepartment of Community Health, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.ORCID https://orcid.org/0000-0003-1425-5912
Marineide G MeloInfectious Diseases Service, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0002-1541-878X
Nathan C BahrDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-9431-8938
David R BoulwareDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-4715-0060
Alessandro C PasqualottoPost-graduation Program in Pathology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0002-6782-5395

Funding

Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (HISTO-FACT)R01AI195133 · NIAID · UNIVERSITY OF MINNESOTA · PI Nathan Bahr, Alessandro Comaru Pasqualotto · 2025 to 2026
$2.5M
Novel Diagnostic Development for TB Meningitis and HistoplasmosisK23NS110470 · NINDS · UNIVERSITY OF MINNESOTA · PI BAHR, NATHAN · 2019 to 2023
$1.0M
Midcareer Mentoring for Clinical Research in HIV/AIDS-related cryptococcal and TB meningitisK24AI184270 · NIAID · UNIVERSITY OF MINNESOTA · PI David R Boulware · 2024 to 2026
$648k
NIAID NIH HHS K24 AI184270NIAID NIH HHS R01 AI195133NINDS NIH HHS K23 NS110470
6 · The paper itself

Abstract

Hierarchical composite end points may better reflect patient outcomes, rather than mortality alone. We applied DOOR and Win-Ratio analyses to a phase II trial comparing single high-dose vs standard liposomal amphotericin B for HIV-associated histoplasmosis. No clear differences were observed, supporting feasibility and informing design of future phase III trials.

Indexed as

histoplasmosisnoninferiority trialrandomized clinical trialstatistical data analysis

Identifiers

PMID41852554
PMCPMC12994473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.